Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 22 | 2023 | 2903 | 1.350 |
Why?
|
| Neoadjuvant Therapy | 7 | 2023 | 318 | 0.510 |
Why?
|
| Receptor, ErbB-2 | 3 | 2023 | 223 | 0.410 |
Why?
|
| Mastectomy | 4 | 2015 | 243 | 0.410 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2022 | 157 | 0.400 |
Why?
|
| Hyperparathyroidism | 3 | 2002 | 67 | 0.400 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2023 | 1313 | 0.370 |
Why?
|
| Mastectomy, Segmental | 3 | 2021 | 93 | 0.360 |
Why?
|
| Parathyroid Neoplasms | 2 | 2002 | 55 | 0.350 |
Why?
|
| Adenoma | 2 | 2002 | 235 | 0.310 |
Why?
|
| Neoplasm Staging | 8 | 2021 | 1939 | 0.290 |
Why?
|
| Aromatase Inhibitors | 1 | 2006 | 28 | 0.290 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2022 | 113 | 0.270 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2017 | 68 | 0.270 |
Why?
|
| Middle Aged | 23 | 2023 | 25028 | 0.230 |
Why?
|
| Female | 32 | 2023 | 44532 | 0.220 |
Why?
|
| Lymph Nodes | 2 | 2017 | 533 | 0.220 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2002 | 15 | 0.220 |
Why?
|
| Carcinoma, Lobular | 2 | 2015 | 81 | 0.220 |
Why?
|
| Mammaplasty | 3 | 2013 | 107 | 0.220 |
Why?
|
| Reoperation | 5 | 2013 | 597 | 0.210 |
Why?
|
| Parathyroidectomy | 1 | 2002 | 78 | 0.210 |
Why?
|
| Radiopharmaceuticals | 1 | 2002 | 180 | 0.200 |
Why?
|
| Parathyroid Hormone | 1 | 2002 | 218 | 0.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 2438 | 0.200 |
Why?
|
| Adenocarcinoma | 5 | 2003 | 1169 | 0.190 |
Why?
|
| Combined Modality Therapy | 10 | 2023 | 1686 | 0.190 |
Why?
|
| Intestinal Neoplasms | 1 | 2001 | 56 | 0.190 |
Why?
|
| Postoperative Complications | 4 | 2013 | 2207 | 0.190 |
Why?
|
| Body Weight | 1 | 2021 | 459 | 0.180 |
Why?
|
| Adult | 19 | 2023 | 25648 | 0.170 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 159 | 0.170 |
Why?
|
| Age Factors | 1 | 2023 | 1851 | 0.160 |
Why?
|
| Humans | 36 | 2023 | 86643 | 0.160 |
Why?
|
| Aged | 15 | 2022 | 18415 | 0.150 |
Why?
|
| Gastrinoma | 1 | 1996 | 2 | 0.150 |
Why?
|
| Zollinger-Ellison Syndrome | 1 | 1996 | 10 | 0.150 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 200 | 0.150 |
Why?
|
| Urinary Catheterization | 1 | 2016 | 35 | 0.140 |
Why?
|
| Prognosis | 6 | 2023 | 3679 | 0.130 |
Why?
|
| Ultrasonography | 1 | 2017 | 695 | 0.130 |
Why?
|
| Radiotherapy | 3 | 2013 | 328 | 0.130 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 6509 | 0.130 |
Why?
|
| Biopsy | 3 | 2018 | 1163 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 930 | 0.120 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 394 | 0.120 |
Why?
|
| Crohn Disease | 1 | 2001 | 730 | 0.120 |
Why?
|
| Phyllodes Tumor | 1 | 2013 | 7 | 0.120 |
Why?
|
| Mass Screening | 1 | 2018 | 618 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2023 | 468 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 3362 | 0.110 |
Why?
|
| Esophageal Neoplasms | 4 | 2003 | 321 | 0.110 |
Why?
|
| Retrospective Studies | 8 | 2022 | 8489 | 0.110 |
Why?
|
| Lymphokines | 3 | 2002 | 76 | 0.110 |
Why?
|
| Neoplasm, Residual | 2 | 2023 | 162 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 508 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 1996 | 645 | 0.100 |
Why?
|
| Endothelial Growth Factors | 2 | 2002 | 55 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 859 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2016 | 751 | 0.090 |
Why?
|
| Genetic Therapy | 2 | 2003 | 342 | 0.090 |
Why?
|
| Paclitaxel | 2 | 2019 | 460 | 0.090 |
Why?
|
| Breast | 2 | 2023 | 288 | 0.090 |
Why?
|
| Mammography | 3 | 2021 | 463 | 0.090 |
Why?
|
| Peptide Fragments | 2 | 2003 | 460 | 0.090 |
Why?
|
| Time Factors | 5 | 2013 | 5210 | 0.080 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 3640 | 0.080 |
Why?
|
| Survival Rate | 3 | 2019 | 1863 | 0.080 |
Why?
|
| Neoplasm Proteins | 2 | 2002 | 532 | 0.070 |
Why?
|
| Endothelium, Vascular | 4 | 2002 | 435 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2023 | 2767 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2021 | 4213 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 6 | 2005 | 1041 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2019 | 552 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2002 | 1197 | 0.070 |
Why?
|
| Tamoxifen | 1 | 2006 | 168 | 0.070 |
Why?
|
| Glycine | 1 | 2005 | 92 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2005 | 299 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2005 | 167 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2003 | 683 | 0.060 |
Why?
|
| Radiation, Ionizing | 2 | 2000 | 121 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2005 | 276 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2015 | 292 | 0.060 |
Why?
|
| Mucin-1 | 1 | 2003 | 44 | 0.060 |
Why?
|
| Mice, Nude | 5 | 2003 | 790 | 0.060 |
Why?
|
| Adolescent | 4 | 2015 | 8981 | 0.050 |
Why?
|
| Intraoperative Period | 1 | 2002 | 90 | 0.050 |
Why?
|
| Collagen | 2 | 2000 | 269 | 0.050 |
Why?
|
| Young Adult | 3 | 2022 | 5976 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2005 | 2360 | 0.050 |
Why?
|
| Body Weights and Measures | 1 | 2021 | 27 | 0.050 |
Why?
|
| Coumarins | 1 | 2000 | 13 | 0.050 |
Why?
|
| Immediate-Early Proteins | 1 | 2002 | 164 | 0.050 |
Why?
|
| Neoplasm Transplantation | 4 | 2005 | 391 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2002 | 268 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2005 | 1076 | 0.050 |
Why?
|
| Male | 6 | 2016 | 40965 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 357 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 26 | 0.040 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1999 | 94 | 0.040 |
Why?
|
| Receptors, Steroid | 1 | 2019 | 42 | 0.040 |
Why?
|
| Trastuzumab | 1 | 2019 | 68 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 295 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 1999 | 269 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 1999 | 227 | 0.040 |
Why?
|
| Mice | 8 | 2005 | 11352 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 322 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2021 | 770 | 0.040 |
Why?
|
| Axilla | 1 | 2017 | 99 | 0.040 |
Why?
|
| Comorbidity | 1 | 2021 | 943 | 0.040 |
Why?
|
| Registries | 1 | 2021 | 702 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 1538 | 0.040 |
Why?
|
| Anorexia | 1 | 1997 | 30 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 1999 | 353 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 752 | 0.040 |
Why?
|
| Transplantation, Heterologous | 3 | 2003 | 363 | 0.040 |
Why?
|
| Thyroidectomy | 1 | 1997 | 170 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2002 | 1376 | 0.040 |
Why?
|
| Urinary Catheters | 1 | 2016 | 6 | 0.040 |
Why?
|
| Decision Trees | 1 | 1996 | 63 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1805 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 1208 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 371 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1621 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 486 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 1997 | 256 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 751 | 0.030 |
Why?
|
| Neoplasms | 2 | 2000 | 2898 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 1996 | 185 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 1997 | 378 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 589 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 1997 | 240 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2002 | 1565 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 1996 | 182 | 0.030 |
Why?
|
| Preoperative Care | 1 | 1996 | 397 | 0.030 |
Why?
|
| Education, Medical | 1 | 2016 | 233 | 0.030 |
Why?
|
| Cytokines | 1 | 1997 | 776 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 4 | 2000 | 3092 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 1135 | 0.030 |
Why?
|
| Animals | 8 | 2005 | 26582 | 0.030 |
Why?
|
| Adenoviridae | 2 | 2003 | 345 | 0.020 |
Why?
|
| Inflammation | 1 | 1997 | 920 | 0.020 |
Why?
|
| Genetic Vectors | 2 | 2003 | 439 | 0.020 |
Why?
|
| Umbilical Veins | 2 | 2000 | 46 | 0.020 |
Why?
|
| Carcinoma, Lewis Lung | 2 | 2000 | 23 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2002 | 56 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 1990 | 48 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 2000 | 2818 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2010 | 63 | 0.020 |
Why?
|
| Radiation Tolerance | 2 | 2002 | 168 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1990 | 315 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 2271 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2003 | 937 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2010 | 261 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2002 | 407 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 3968 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2000 | 1014 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2000 | 1961 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1565 | 0.020 |
Why?
|
| Escherichia coli | 2 | 2000 | 597 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 1991 | 0.020 |
Why?
|
| Radiodermatitis | 1 | 2005 | 10 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2005 | 102 | 0.020 |
Why?
|
| Contrast Media | 1 | 2010 | 1078 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2005 | 370 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2005 | 303 | 0.020 |
Why?
|
| Apoptosis | 2 | 2002 | 1683 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2005 | 458 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 5417 | 0.010 |
Why?
|
| Wound Healing | 1 | 2005 | 344 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 999 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 144 | 0.010 |
Why?
|
| Random Allocation | 1 | 2003 | 332 | 0.010 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2002 | 54 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 1999 | 1981 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 305 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 154 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 263 | 0.010 |
Why?
|
| Virus Replication | 1 | 2003 | 319 | 0.010 |
Why?
|
| Isocoumarins | 1 | 2000 | 7 | 0.010 |
Why?
|
| Collagen Type XVIII | 1 | 2000 | 4 | 0.010 |
Why?
|
| Endostatins | 1 | 2000 | 6 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 222 | 0.010 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2000 | 44 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2000 | 188 | 0.010 |
Why?
|
| Chicago | 1 | 2005 | 1379 | 0.010 |
Why?
|
| Pichia | 1 | 2000 | 29 | 0.010 |
Why?
|
| Laminin | 1 | 2000 | 85 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2000 | 224 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2000 | 121 | 0.010 |
Why?
|
| Microcirculation | 1 | 2000 | 106 | 0.010 |
Why?
|
| Cell Separation | 1 | 2000 | 196 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1999 | 35 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2000 | 646 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1999 | 87 | 0.010 |
Why?
|
| Cell Survival | 1 | 2002 | 969 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1999 | 104 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2000 | 679 | 0.010 |
Why?
|
| Disease Progression | 1 | 2002 | 1531 | 0.010 |
Why?
|
| Ciliary Neurotrophic Factor | 1 | 1997 | 1 | 0.010 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 1997 | 4 | 0.010 |
Why?
|
| Glioblastoma | 1 | 1999 | 255 | 0.010 |
Why?
|
| Cell Movement | 1 | 2000 | 758 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 1997 | 41 | 0.010 |
Why?
|
| Leptin | 1 | 1997 | 105 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1997 | 127 | 0.010 |
Why?
|
| Interleukins | 1 | 1997 | 134 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1997 | 249 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 1997 | 149 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2000 | 1753 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1997 | 286 | 0.010 |
Why?
|
| Melanoma | 1 | 1999 | 459 | 0.010 |
Why?
|
| Recurrence | 1 | 1997 | 1139 | 0.010 |
Why?
|
| Kinetics | 1 | 1997 | 1513 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 1997 | 503 | 0.010 |
Why?
|
| Proteins | 1 | 1997 | 777 | 0.010 |
Why?
|
| Chromatography, Thin Layer | 1 | 1990 | 32 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2002 | 3241 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2002 | 7993 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1999 | 2262 | 0.000 |
Why?
|
| Diabetes Mellitus | 1 | 1990 | 806 | 0.000 |
Why?
|